Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
P/B ratio for Verona Pharma plc (VRNA)
P/B ratio as of 2023: 6.32
According to Verona Pharma plc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.32. At the end of 2022 the company had a P/B ratio of 7.50.
P/B ratio history for Verona Pharma plc from 2005 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 6.32 |
| 2022 | 7.50 |
| 2021 | 2.69 |
| 2020 | 1.24 |
| 2019 | 1.29 |
| 2018 | 12.45 |
| 2017 | 9.28 |
| 2016 | 538.39 |
| 2015 | 1397.33 |
| 2014 | 478.41 |
| 2013 | 1020.90 |
| 2012 | 756.11 |
| 2011 | 419.79 |
| 2010 | 484.43 |
| 2009 | 310.51 |
| 2008 | 412.47 |
| 2007 | 214.06 |
| 2006 | 87.14 |
| 2005 | 260.07 |